Cory Berkland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11398804/publications.pdf

Version: 2024-02-01

109	5,839	76294	79644
papers	citations	40 h-index	73 g-index

109	109	109	7625
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes. Diabetes, 2021, 70, 1334-1346.	0.3	11
2	CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments. Oncogene, 2020, 39, 2275-2289.	2.6	24
3	Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells. Molecular Pharmaceutics, 2019, 16, 1563-1572.	2.3	14
4	Role of ALDH1A1 and HTRA2 expression to CCL2/CCR2 mediated breast cancer cell growth and invasion. Biology Open, 2019, 8, .	0.6	15
5	Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells. ACS Chemical Biology, 2019, 14, 1436-1448.	1.6	9
6	Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator. Journal of Controlled Release, 2019, 306, 165-176.	4.8	48
7	Acute B-Cell Inhibition by Soluble Antigen Arrays Is Valency-Dependent and Predicts Immunomodulation in Splenocytes. Biomacromolecules, 2019, 20, 2115-2122.	2.6	7
8	Controlled release of poly(vinyl sulfonate) scale inhibitor to extend reservoir treatment lifetime. Journal of Applied Polymer Science, 2019, 136, 47225.	1.3	10
9	Design of a Cytocompatible Hydrogel Coating to Modulate Properties of Ceramic-Based Scaffolds for Bone Repair. Cellular and Molecular Bioengineering, 2018, 11, 211-217.	1.0	20
10	Application of Polyelectrolyte Complex Nanoparticles to Increase the Lifetime of Poly Vinyl Sulfonate Scale Inhibitor. , 2018, , .		7
11	Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis. Journal of Autoimmunity, 2018, 93, 76-88.	3.0	31
12	Screening Immunomodulators To Skew the Antigen-Specific Autoimmune Response. Molecular Pharmaceutics, 2017, 14, 66-80.	2.3	6
13	Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis. Biomacromolecules, 2017, 18, 1893-1907.	2.6	22
14	Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis. Journal of Controlled Release, 2017, 266, 156-165.	4.8	13
15	Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration. Advanced Drug Delivery Reviews, 2017, 120, 50-70.	6.6	119
16	Pulmonary Administration of Soluble Antigen Arrays Is Superior toÂAntigen in Treatment of Experimental Autoimmune Encephalomyelitis. Journal of Pharmaceutical Sciences, 2017, 106, 3293-3302.	1.6	18
17	Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget, 2016, 7, 49349-49367.	0.8	95
18	Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. Molecular Pharmaceutics, 2016, 13, 1904-1914.	2.3	30

#	Article	IF	Citations
19	Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis. Journal of Pharmaceutical Sciences, 2016, 105, 3399-3408.	1.6	9
20	Overcoming formulation challenges for the next generation of vaccines. Expert Opinion on Drug Delivery, 2016, 13, 1501-1502.	2.4	0
21	Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells. Journal of Pharmaceutical Sciences, 2016, 105, 3645-3657.	1.6	15
22	Antigen-Specific Binding of Multivalent Soluble Antigen Arrays Induces Receptor Clustering and Impedes B Cell Receptor Mediated Signaling. Biomacromolecules, 2016, 17, 710-722.	2.6	22
23	Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity. Advanced Drug Delivery Reviews, 2016, 98, 86-98.	6.6	66
24	Molecular Dynamics of Multivalent Soluble Antigen Arrays Support a Two-Signal Co-delivery Mechanism in the Treatment of Experimental Autoimmune Encephalomyelitis. Molecular Pharmaceutics, 2016, 13, 330-343.	2.3	13
25	Routes of Administration and Dose Optimization of Soluble Antigen Arrays in Mice with Experimental Autoimmune Encephalomyelitis. Journal of Pharmaceutical Sciences, 2015, 104, 714-721.	1.6	17
26	NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 341-352.	0.7	14
27	Multivalent Nanomaterials: Learning from Vaccines and Progressing to Antigen-Specific Immunotherapies. Journal of Pharmaceutical Sciences, 2015, 104, 346-361.	1.6	37
28	Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits. Molecular Pharmaceutics, 2015, 12, 2665-2674.	2.3	16
29	The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Research and Treatment, 2015, 150, 309-320.	1.1	30
30	Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14008.	1.8	35
31	Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis. AAPS Journal, 2014, 16, 1185-1193.	2.2	26
32	Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis. AAPS Journal, 2014, 16, 1204-1213.	2.2	26
33	DNA complexed with TAT peptide and condensed using calcium possesses unique structural features compared to PEI polyplexes. International Journal of Pharmaceutics, 2014, 465, 11-17.	2.6	8
34	Hyaluronic acid colloidal gels as selfâ€assembling elastic biomaterials. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2014, 102, 612-618.	1.6	16
35	NanoClusters Surface Area Allows Nanoparticle Dissolution with Microparticle Properties. Journal of Pharmaceutical Sciences, 2014, 103, 1787-1798.	1.6	12
36	Hyaluronic Acid Graft Polymers Displaying Peptide Antigen Modulate Dendritic Cell Response in Vitro. Molecular Pharmaceutics, 2014, 11, 367-373.	2.3	16

#	Article	IF	Citations
37	NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical ventilation. International Journal of Pharmaceutics, 2014, 462, 19-28.	2.6	14
38	Hybrid Hydroxyapatite Nanoparticle Colloidal Gels are Injectable Fillers for Bone Tissue Engineering. Tissue Engineering - Part A, 2013, 19, 2586-2593.	1.6	69
39	Synthesis and characterization of poly(Nâ€vinyl formamide) hydrogelsâ€"A potential alternative to polyacrylamide hydrogels. Journal of Polymer Science Part A, 2013, 51, 435-445.	2.5	7
40	Single-step grafting of aminooxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. Journal of Controlled Release, 2013, 168, 334-340.	4.8	30
41	Hyaluronic Acid Nanoparticles Titrate the Viscoelastic Properties of Viscosupplements. Langmuir, 2013, 29, 5123-5131.	1.6	25
42	Poly(vinylamine) microgels: pH-responsive particles with high primary amine contents. Soft Matter, 2013, 9, 3920.	1.2	31
43	Intratracheal Administration of a Nanoparticle-Based Therapy with the Angiotensin II Type 2 Receptor Gene Attenuates Lung Cancer Growth. Cancer Research, 2012, 72, 2057-2067.	0.4	68
44	Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide To Treat Experimental Autoimmune Encephalomyelitis. Molecular Pharmaceutics, 2012, 9, 979-985.	2.3	65
45	Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine, 2012, 7, 1297-1309.	1.7	39
46	Development of Budesonide Nanocluster Dry Powder Aerosols: Processing. Journal of Pharmaceutical Sciences, 2012, 101, 3425-3433.	1.6	11
47	Development of Budesonide Nanocluster Dry Powder Aerosols: Formulation and Stability. Journal of Pharmaceutical Sciences, 2012, 101, 3445-3455.	1.6	16
48	Development of Budesonide Nanocluster Dry Powder Aerosols: Preformulation. Journal of Pharmaceutical Sciences, 2012, 101, 3434-3444.	1.6	10
49	Chemically modifiable fluorinated copolymer nanoparticles for ¹⁹Fâ€MRI contrast enhancement. Journal of Applied Polymer Science, 2012, 126, 1218-1227.	1.3	8
50	Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. International Journal of Pharmaceutics, 2012, 427, 134-142.	2.6	50
51	Nanocluster Budesonide Formulations Enhance Drug Delivery through Endotracheal Tubes. Journal of Pharmaceutical Sciences, 2012, 101, 1063-1072.	1.6	12
52	Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response. ACS Nano, 2011, 5, 1693-1702.	7.3	22
53	Particle Engineering Technologies for Pulmonary Drug Delivery. , 2011, , 283-312.		5
54	Noncovalent PEGylation by Polyanion Complexation as a Means To Stabilize Keratinocyte Growth Factor-2 (KGF-2). Biomacromolecules, 2011, 12, 3880-3894.	2.6	26

#	Article	IF	Citations
55	Calcium Condensed LABL-TAT Complexes Effectively Target Gene Delivery to ICAM-1 Expressing Cells. Molecular Pharmaceutics, 2011, 8, 788-798.	2.3	38
56	Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. European Journal of Pharmaceutical Sciences, 2011, 44, 522-533.	1.9	35
57	Controlling Ligand Surface Density Optimizes Nanoparticle Binding to ICAM-1. Journal of Pharmaceutical Sciences, 2011, 100, 1045-1056.	1.6	78
58	Calcium Condensation of DNA Complexed with Cell-Penetrating Peptides Offers Efficient, Noncytotoxic Gene Delivery. Journal of Pharmaceutical Sciences, 2011, 100, 1637-1642.	1.6	34
59	PLGAâ€chitosan/PLGAâ€alginate nanoparticle blends as biodegradable colloidal gels for seeding human umbilical cord mesenchymal stem cells. Journal of Biomedical Materials Research - Part A, 2011, 96A, 520-527.	2.1	126
60	Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Therapeutic Delivery, 2011, 2, 873-889.	1.2	20
61	Research Spotlight: Therapeutic Particles and Biomaterials Technology Laboratory at The University of Kansas. Therapeutic Delivery, 2010, 1, 29-35.	1.2	0
62	LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery. Current Pharmaceutical Design, 2010, 16, 2321-2330.	0.9	18
63	Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. International Journal of Pharmaceutics, 2010, 391, 305-312.	2.6	28
64	Next Steps for Pharmaceutical Nanotechnology. Journal of Pharmaceutical Innovation, 2010, 5, 70-71.	1.1	1
65	Threeâ€dimensional macroscopic scaffolds with a gradient in stiffness for functional regeneration of interfacial tissues. Journal of Biomedical Materials Research - Part A, 2010, 94A, 870-876.	2.1	38
66	Effects of divalent cations, seawater, and formation brine on positively charged polyethylenimine/dextran sulfate/chromium(III) polyelectrolyte complexes and partially hydrolyzed polyacrylamide/chromium(III) gelation. Journal of Applied Polymer Science, 2010, 115, 1008-1014.	1.3	33
67	Low charge polyvinylamine nanogels offer sustained, lowâ€level gene expression. Journal of Applied Polymer Science, 2010, 118, 1921-1932.	1.3	5
68	Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. Journal of Pharmaceutical Sciences, 2010, 99, 2413-2422.	1.6	28
69	Fluorinated Copolymer Nanoparticles for Multimodal Imaging Applications. Macromolecular Rapid Communications, 2010, 31, 87-92.	2.0	14
70	Microsphere-based scaffolds for cartilage tissue engineering: Using subcritical CO2 as a sintering agent. Acta Biomaterialia, 2010, 6, 137-143.	4.1	85
71	Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects. Biomaterials, 2010, 31, 4980-4986.	5.7	159
72	Production and characterization of polymer microspheres containing trace explosives using precision particle fabrication technology. Journal of Microencapsulation, 2010, 27, 426-435.	1.2	11

#	Article	IF	Citations
73	Reduction of diffusion barriers in isolated rat islets improves survival, but not insulin secretion or transplantation outcome. Organogenesis, 2010, 6, 115-124.	0.4	58
74	Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biology and Therapy, 2010, 9, 277-285.	1.5	58
75	cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells. Molecular Pharmaceutics, 2010, 7, 146-155.	2.3	14
76	Agglomerates of Ciprofloxacin Nanoparticles Yield Fine Dry Powder Aerosols. Journal of Pharmaceutical Innovation, 2010, 5, 79-87.	1.1	28
77	Iodinated NanoClusters as an Inhaled Computed Tomography Contrast Agent for Lung Visualization. Molecular Pharmaceutics, 2010, 7, 1274-1282.	2.3	32
78	Controlled release of RepiferminÂ® from polyelectrolyte complexes stimulates endothelial cell proliferation. Journal of Pharmaceutical Sciences, 2009, 98, 268-280.	1.6	28
79	Budesonide Nanoparticle Agglomerates as Dry Powder Aerosols With Rapid Dissolution. Journal of Pharmaceutical Sciences, 2009, 98, 2731-2746.	1.6	76
80	Adhesion of pancreatic beta cells to biopolymer films. Biopolymers, 2009, 91, 676-685.	1.2	44
81	Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration. Pharmaceutical Research, 2009, 26, 1752-1763.	1.7	73
82	â€œSoftâ€•Calcium Crosslinks Enable Highly Efficient Gene Transfection Using TAT Peptide. Pharmaceutical Research, 2009, 26, 2619-2629.	1.7	34
83	Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. International Journal of Pharmaceutics, 2009, 369, 136-143.	2.6	65
84	Magnetic resonance imaging of contrast-enhanced polyelectrolyte complexes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2008, 4, 30-40.	1.7	23
85	Poly(<scp>d,l</scp>-lactide-co-glycolide) Nanoparticle Agglomerates as Carriers in Dry Powder Aerosol Formulation of Proteins. Langmuir, 2008, 24, 9775-9783.	1.6	22
86	Nanotechnology in vaccine delivery. Advanced Drug Delivery Reviews, 2008, 60, 915-928.	6.6	479
87	Delayed HPAM Gelation via Transient Sequestration of Chromium in Polyelectrolyte Complex Nanoparticles. Macromolecules, 2008, 41, 4398-4404.	2.2	76
88	Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery. Langmuir, 2008, 24, 13614-13620.	1.6	53
89	PLGA Nanoparticleâ^'Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1. Bioconjugate Chemistry, 2008, 19, 145-152.	1.8	176
90	Poly(N-vinylformamide) Nanogels Capable of pH-Sensitive Protein Release. Macromolecules, 2008, 41, 6546-6554.	2.2	83

#	Article	IF	Citations
91	Microsphere-Based Seamless Scaffolds Containing Macroscopic Gradients of Encapsulated Factors for Tissue Engineering. Tissue Engineering - Part C: Methods, 2008, 14, 299-309.	1.1	106
92	Strategies and Applications for Incorporating Physical and Chemical Signal Gradients in Tissue Engineering. Tissue Engineering - Part B: Reviews, 2008, 14, 341-366.	2.5	170
93	Polyelectrolyte Complexes Stabilize and Controllably Release Vascular Endothelial Growth Factor. Biomacromolecules, 2007, 8, 1607-1614.	2.6	100
94	Biodegradable Nanoparticle Flocculates for Dry Powder Aerosol Formulation. Langmuir, 2007, 23, 10897-10901.	1.6	53
95	Acid-Labile Polyvinylamine Micro- and Nanogel Capsules. Macromolecules, 2007, 40, 4635-4643.	2.2	60
96	Macromolecule Release from Monodisperse PLG Microspheres: Control of Release Rates and Investigation of Release Mechanism. Journal of Pharmaceutical Sciences, 2007, 96, 1176-1191.	1.6	56
97	NanoCipro encapsulation in monodisperse large porous PLGA microparticles. Journal of Controlled Release, 2007, 121, 100-109.	4.8	115
98	Monodisperse Liquid-filled Biodegradable Microcapsules. Pharmaceutical Research, 2007, 24, 1007-1013.	1.7	57
99	Cell Adhesion Molecules for Targeted Drug Delivery. Journal of Pharmaceutical Sciences, 2006, 95, 1856-1872.	1.6	108
100	In vitro degradation of polyanhydride/polyester core-shell double-wall microspheres. International Journal of Pharmaceutics, 2005, 301, 294-303.	2.6	18
101	Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. Journal of Controlled Release, 2005, 103, 149-158.	4.8	144
102	Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres. Journal of Controlled Release, 2004, 94, 129-141.	4.8	170
103	Uniform double-walled polymer microspheres of controllable shell thickness. Journal of Controlled Release, 2004, 96, 101-111.	4.8	120
104	Three-month, zero-order piroxicam release from monodispersed double-walled microspheres of controlled shell thickness. Journal of Biomedical Materials Research Part B, 2004, 70A, 576-584.	3.0	47
105	Controlling surface nano-structure using flow-limited field-injection electrostatic spraying (FFESS) of poly(,-lactide-co-glycolide). Biomaterials, 2004, 25, 5649-5658.	5.7	108
106	Precision Polymer Microparticles for Controlled-Release Drug Delivery. ACS Symposium Series, 2004, , 197-213.	0.5	5
107	PLG microsphere size controls drug release rate through several competing factors. Pharmaceutical Research, 2003, 20, 1055-1062.	1.7	182
108	Precise control of PLG microsphere size provides enhanced control of drug release rate. Journal of Controlled Release, 2002, 82, 137-147.	4.8	348

#	Article	IF	Citations
109	Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. Journal of Controlled Release, 2001, 73, 59-74.	4.8	314